Navigation Links
REMICADE-Treated Patients Experienced Rapid and Substantial Improvement in Psoriasis in Critical Regions of Body
Date:2/4/2008

cal

remission in adult and pediatric patients with moderately to severely

active CD who have had an inadequate response to conventional therapy.

-- Reducing the number of draining enterocutaneous and rectovaginal

fistulas and maintaining fistula closure in adult patients with

fistulizing CD.

-- Reducing signs and symptoms, inducing and maintaining clinical

remission and mucosal healing, and eliminating corticosteroid use in

patients with moderately to severely active UC who have had an

inadequate response to conventional therapy.

-- Reducing signs and symptoms of active arthritis, inhibiting the

progression of structural damage and improving physical function in

patients with PsA.

-- Treatment of adult patients with chronic severe plaque PsO who are

candidates for systemic therapy and when other systemic therapies are

medically less appropriate.

REMICADE is unique among available anti-TNF biologic therapies. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE is a two-hour infusion administered every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year.

Important Safety Information

There are reports of serious infections, including tuberculosis (TB), sepsis and pneumonia. Some of these infections have been fatal. Tell your doctor if you have had recent or past exposure to people with TB. Your doctor will evaluate you for TB and perform a TB test. If you have latent (inactive) TB, your doctor should begin TB treatment before you start REMICADE. REMICADE can lower your ability to fight infections, so if you are prone to or have a h
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Observational Data Show Transfusion Patterns in Chemotherapy-Induced Anemia Patients Receiving Erythropoiesis-Stimulating Agents
2. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
3. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
4. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  In 2008, two of Dr. Gurney,s employees reported ... substances, on a regular basis, that were not used ... was practicing "all the time" while under the influence. ... said that Dr. Gurney was prone to "making mistakes ... Dr. Gurney,s behavior became increasingly erratic and unfocused, and ...
(Date:10/25/2014)... , Oct. 24, 2014 In conjunction ... quarter 2014 financial results press release, you are invited ... broadcast live over the internet on Monday, November 3, ... Time). A live audio webcast of the ... http://www.durect.com and clicking "Investor Relations."  If you ...
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research Institute, ... Drug Administration (FDA) has given the company permission to ... in patients > 3 months of age with a ... placed in one of five treatment groups based on ... prior treatment for DIPG. The primary study endpoint is ...
Breaking Medicine Technology:Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 ... biology, today announced Dr. Xun Wang ... all Research & Development. , Triton has developed a ... value algae-based proteins. According to Dr. Wang, the platform ... traditional expression systems. He says, “Algae are unique because ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The global ... CAGR of 7.6%, to reach $50.4 billion by 2018 ... healthcare systems industry, and pharmaceutical industry are driving the ... model to enhance their focus on core business, reduce ... and trained staff (further reducing hiring and training costs), ...
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded the Connecticut ... the field of establishing recovery community organizations. Bob had ... he retired, he set out to answer a couple questions ... , 1. Where are the people in recovery when ... Can the recovery community be organized to advocate for issues ...
(Date:10/25/2014)... 2014 Market Research Report ... 2009-2019 is a professional and in-depth market ... industry. The report firstly reviews the basic ... application and manufacturing technology. The report then ... Molecular Diagnostics listing their product specification, capacity, ...
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
Breaking Medicine News(10 mins):Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4
... Resources, an,association management and consulting firm for non-profit organizations,located ... launch of an,innovative e-learning solution to be used by ... of the service will offer a way to,increase revenue ... , "We,re excited about this ...
... CORTLANDT MANOR, N.Y., Feb. 3 Polymedco is pleased to ... and screening. It is designed to educate both patients ... cancer. The website is located at www.fobt-tests.com . ... cancer related death today in the United States. However, ...
... of change echoing across the country, Americans have been ... greatness of this nation. America,s ability to seize this ... by each individual. In celebration of the inherent excellence ... forum in which everyday stories of greatness will be ...
... Aldridge LLP (MLA) is pleased to announce that Paul ... has joined the firm in our Government Contracts Department. ... firm,s Life Sciences and Public Health Preparedness practice in ... addition to helping clients develop strategies for offering their ...
... Mich., Feb. 3 Cherries are not only good for ... According to recent,data, more than 9 out of 10 Americans ... say they,re purchasing "locally produced" products,and the majority are defining ... About ninety-five percent of cherries consumed in ...
... 3 To mark American Heart,Month, deCODE genetics (Nasdaq: ... of,February it will offer its deCODEme Cardio Scan(TM), the ... inherited risk of heart,attack, stroke and atrial fibrillation, intracranial ... promotional price of,$100. , On ...
Cached Medicine News:Health News:Center for Association Resources Launches E-Learning Service 2Health News:Nature Made(R) Seeking Stories of Individual Greatness for Upcoming Documentary 2Health News:Nature Made(R) Seeking Stories of Individual Greatness for Upcoming Documentary 3Health News:Former Assistant Secretary of Defense for Homeland Defense Joins McKenna Long & Aldridge LLP 2Health News:Cherries: 'America's Super Fruit' Offers Homegrown Health Benefits 2Health News:Cherries: 'America's Super Fruit' Offers Homegrown Health Benefits 3Health News:deCODEme(TM) Takes on Heart Disease in February 2Health News:deCODEme(TM) Takes on Heart Disease in February 3Health News:deCODEme(TM) Takes on Heart Disease in February 4Health News:deCODEme(TM) Takes on Heart Disease in February 5
... Family of infusion pumps are ... collective series of administration sets. ... offers a wide variety of ... each featuring the patented Flo-Stop ...
... The Signature Edition GOLD Infusion ... from customer input, as well as ... Human factors design refers to ... with controls and displays engineered to ...
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
Developed in a Microsoft Windows environment, MedInformatix provides physician practices a Computerized Patient Record (CPR) with a Practice Management System (PMS) that is both integrated and design...
Medicine Products: